Inter Parfums Q2 Sales $207.60M Up From $49.51M YoY

Inter Parfums (NASDAQ:IPAR) reported $207.60 million in sales this quarter. This is a 319.34 percent increase over sales of $49.51 million the same period last year.

byBenzinga Newsdesk

July 19, 2021

1 minute read

Inter Parfums (NASDAQ:IPAR) reported $207.60 million in sales this quarter. This is a 319.34 percent increase over sales of $49.51 million the same period last year.

Oppenheimer Maintains Outperform on Coupa Software, Raises Price Target to $300

By vishwanath@benzinga.com

Today, 9:47 PM

Oppenheimer analyst Brian Schwartz maintains Coupa Software (NASDAQ:COUP) with a Outperform and raises the price target from $260 to $300.

COUP

RBC Capital Upgrades Charter Communications to Outperform, Lowers Price Target to $690

By Benzinga Newsdesk

Today, 9:47 PM

RBC Capital analyst Kutgun Maral upgrades Charter Communications (NASDAQ:CHTR) from Sector Perform to Outperform and lowers the price target from $770 to $690.

CHTR

Micron Technology, Novavax, CarGurus And Some Other Big Losers From Tuesday

By Lisa Levin

Today, 9:47 PM

U.S. stocks closed lower, with the Nasdaq dropping 150 points on Tuesday. Here is the list of some big stocks moving lower in the previous session.

AEO

Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Glabellar Lines

By Ragothaman Srinivasan

Today, 9:47 PM

Revance Therapeutics, Inc. (NASDAQ: RVNC) announced acceptance of Biologics License Application (BLA) by the U.S. Food and Drug Administration (FDA) of its drug candidate DaxibotulinumtoxinA for Injection for the treatment of patients with moderate to severe glabellar lines.

RVNC

Inter Parfums Q2 Sales $207.60M Up From $49.51M YoY

Related Posts

Oppenheimer Maintains Outperform on Coupa Software, Raises Price Target to $300

RBC Capital Upgrades Charter Communications to Outperform, Lowers Price Target to $690

Micron Technology, Novavax, CarGurus And Some Other Big Losers From Tuesday

Revance Receives FDA Acceptance of BLA Resubmission for DaxibotulinumtoxinA for Glabellar Lines